Monitoring early tumor response to vascular targeted therapy using super-resolution ultrasound imaging

Debabrata Ghosh, Fangyuan Xiong, Shashank R. Sirsi, Robert Mattrey, Rolf Brekken, Jung Whan Kim, Kenneth Hoyt

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Citation (Scopus)

Abstract

The current standard for evaluating breast tumor response to neoadjuvant treatment remains the assessment of a tumor size change several weeks after therapy begins. However, the tumor microenvironment (including microvasculature) is known to change drastically before any detectable change in physical size manifests. To that end, we have developed a new high-resolution ultrasound (US) imaging modality in our laboratory, termed super-resolution ultrasound (SR-US), for improved visualization of the tumor angiogenic network. A clinical US scanner (Acuson Sequoia 512, Siemens Healthcare) equipped with a 15L8-S linear array transducer was used for our study. Operation of this system was done using a nonlinear harmonic imaging. A low transmit power (mechanical index < 0.2) was used to minimize any MB destruction during imaging. After a slow injection of a MB contrast via a tail vein catheter placed in breast cancer-bearing mice (N = 10), each tumor was US imaged for 10 min at baseline and again at 1 and 2 h after dosing with an antiangiogenic drug (bevacizumab, Genentech Inc) or sham control drug. After collecting a stack of US images, images corrupted by respiratory motion were removed using curve fit-based filtering. A singular value decomposition (SVD)-based spatiotemporal filter was then used to localize individual MBs. Subsequently, a SR-US image (i.e., MB density map) was generated by mapping the cumulative MB localizations. SR-US images were reviewed and longitudinal changes in the tumor microvascular network in response to treatment were evaluated. Overall, an acute microvascular response to bevacizumab was found within 2 h of drug dosing. This observation was consistent with immunohistologic findings and suggests that in vivo SR-US imaging has enormous potential in monitoring the early tumor response to drug treatment.

Original languageEnglish (US)
Title of host publication2017 IEEE International Ultrasonics Symposium, IUS 2017
PublisherIEEE Computer Society
ISBN (Electronic)9781538633830
DOIs
StatePublished - Oct 31 2017
Event2017 IEEE International Ultrasonics Symposium, IUS 2017 - Washington, United States
Duration: Sep 6 2017Sep 9 2017

Other

Other2017 IEEE International Ultrasonics Symposium, IUS 2017
CountryUnited States
CityWashington
Period9/6/179/9/17

Fingerprint

therapy
tumors
drugs
image resolution
breast
linear arrays
veins
scanners
destruction
mice
transducers
cancer
injection
harmonics
decomposition
filters
high resolution
curves

Keywords

  • Angiogenesis
  • Bevacizumab
  • Contrast Agents
  • Microbubbles
  • Microvascular Imaging
  • Super-Resolution Ultrasound

ASJC Scopus subject areas

  • Acoustics and Ultrasonics

Cite this

Ghosh, D., Xiong, F., Sirsi, S. R., Mattrey, R., Brekken, R., Kim, J. W., & Hoyt, K. (2017). Monitoring early tumor response to vascular targeted therapy using super-resolution ultrasound imaging. In 2017 IEEE International Ultrasonics Symposium, IUS 2017 [8092944] IEEE Computer Society. https://doi.org/10.1109/ULTSYM.2017.8092944

Monitoring early tumor response to vascular targeted therapy using super-resolution ultrasound imaging. / Ghosh, Debabrata; Xiong, Fangyuan; Sirsi, Shashank R.; Mattrey, Robert; Brekken, Rolf; Kim, Jung Whan; Hoyt, Kenneth.

2017 IEEE International Ultrasonics Symposium, IUS 2017. IEEE Computer Society, 2017. 8092944.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Ghosh, D, Xiong, F, Sirsi, SR, Mattrey, R, Brekken, R, Kim, JW & Hoyt, K 2017, Monitoring early tumor response to vascular targeted therapy using super-resolution ultrasound imaging. in 2017 IEEE International Ultrasonics Symposium, IUS 2017., 8092944, IEEE Computer Society, 2017 IEEE International Ultrasonics Symposium, IUS 2017, Washington, United States, 9/6/17. https://doi.org/10.1109/ULTSYM.2017.8092944
Ghosh D, Xiong F, Sirsi SR, Mattrey R, Brekken R, Kim JW et al. Monitoring early tumor response to vascular targeted therapy using super-resolution ultrasound imaging. In 2017 IEEE International Ultrasonics Symposium, IUS 2017. IEEE Computer Society. 2017. 8092944 https://doi.org/10.1109/ULTSYM.2017.8092944
Ghosh, Debabrata ; Xiong, Fangyuan ; Sirsi, Shashank R. ; Mattrey, Robert ; Brekken, Rolf ; Kim, Jung Whan ; Hoyt, Kenneth. / Monitoring early tumor response to vascular targeted therapy using super-resolution ultrasound imaging. 2017 IEEE International Ultrasonics Symposium, IUS 2017. IEEE Computer Society, 2017.
@inproceedings{1913d7d51ef840f88eb03149c2bb55d6,
title = "Monitoring early tumor response to vascular targeted therapy using super-resolution ultrasound imaging",
abstract = "The current standard for evaluating breast tumor response to neoadjuvant treatment remains the assessment of a tumor size change several weeks after therapy begins. However, the tumor microenvironment (including microvasculature) is known to change drastically before any detectable change in physical size manifests. To that end, we have developed a new high-resolution ultrasound (US) imaging modality in our laboratory, termed super-resolution ultrasound (SR-US), for improved visualization of the tumor angiogenic network. A clinical US scanner (Acuson Sequoia 512, Siemens Healthcare) equipped with a 15L8-S linear array transducer was used for our study. Operation of this system was done using a nonlinear harmonic imaging. A low transmit power (mechanical index < 0.2) was used to minimize any MB destruction during imaging. After a slow injection of a MB contrast via a tail vein catheter placed in breast cancer-bearing mice (N = 10), each tumor was US imaged for 10 min at baseline and again at 1 and 2 h after dosing with an antiangiogenic drug (bevacizumab, Genentech Inc) or sham control drug. After collecting a stack of US images, images corrupted by respiratory motion were removed using curve fit-based filtering. A singular value decomposition (SVD)-based spatiotemporal filter was then used to localize individual MBs. Subsequently, a SR-US image (i.e., MB density map) was generated by mapping the cumulative MB localizations. SR-US images were reviewed and longitudinal changes in the tumor microvascular network in response to treatment were evaluated. Overall, an acute microvascular response to bevacizumab was found within 2 h of drug dosing. This observation was consistent with immunohistologic findings and suggests that in vivo SR-US imaging has enormous potential in monitoring the early tumor response to drug treatment.",
keywords = "Angiogenesis, Bevacizumab, Contrast Agents, Microbubbles, Microvascular Imaging, Super-Resolution Ultrasound",
author = "Debabrata Ghosh and Fangyuan Xiong and Sirsi, {Shashank R.} and Robert Mattrey and Rolf Brekken and Kim, {Jung Whan} and Kenneth Hoyt",
year = "2017",
month = "10",
day = "31",
doi = "10.1109/ULTSYM.2017.8092944",
language = "English (US)",
booktitle = "2017 IEEE International Ultrasonics Symposium, IUS 2017",
publisher = "IEEE Computer Society",

}

TY - GEN

T1 - Monitoring early tumor response to vascular targeted therapy using super-resolution ultrasound imaging

AU - Ghosh, Debabrata

AU - Xiong, Fangyuan

AU - Sirsi, Shashank R.

AU - Mattrey, Robert

AU - Brekken, Rolf

AU - Kim, Jung Whan

AU - Hoyt, Kenneth

PY - 2017/10/31

Y1 - 2017/10/31

N2 - The current standard for evaluating breast tumor response to neoadjuvant treatment remains the assessment of a tumor size change several weeks after therapy begins. However, the tumor microenvironment (including microvasculature) is known to change drastically before any detectable change in physical size manifests. To that end, we have developed a new high-resolution ultrasound (US) imaging modality in our laboratory, termed super-resolution ultrasound (SR-US), for improved visualization of the tumor angiogenic network. A clinical US scanner (Acuson Sequoia 512, Siemens Healthcare) equipped with a 15L8-S linear array transducer was used for our study. Operation of this system was done using a nonlinear harmonic imaging. A low transmit power (mechanical index < 0.2) was used to minimize any MB destruction during imaging. After a slow injection of a MB contrast via a tail vein catheter placed in breast cancer-bearing mice (N = 10), each tumor was US imaged for 10 min at baseline and again at 1 and 2 h after dosing with an antiangiogenic drug (bevacizumab, Genentech Inc) or sham control drug. After collecting a stack of US images, images corrupted by respiratory motion were removed using curve fit-based filtering. A singular value decomposition (SVD)-based spatiotemporal filter was then used to localize individual MBs. Subsequently, a SR-US image (i.e., MB density map) was generated by mapping the cumulative MB localizations. SR-US images were reviewed and longitudinal changes in the tumor microvascular network in response to treatment were evaluated. Overall, an acute microvascular response to bevacizumab was found within 2 h of drug dosing. This observation was consistent with immunohistologic findings and suggests that in vivo SR-US imaging has enormous potential in monitoring the early tumor response to drug treatment.

AB - The current standard for evaluating breast tumor response to neoadjuvant treatment remains the assessment of a tumor size change several weeks after therapy begins. However, the tumor microenvironment (including microvasculature) is known to change drastically before any detectable change in physical size manifests. To that end, we have developed a new high-resolution ultrasound (US) imaging modality in our laboratory, termed super-resolution ultrasound (SR-US), for improved visualization of the tumor angiogenic network. A clinical US scanner (Acuson Sequoia 512, Siemens Healthcare) equipped with a 15L8-S linear array transducer was used for our study. Operation of this system was done using a nonlinear harmonic imaging. A low transmit power (mechanical index < 0.2) was used to minimize any MB destruction during imaging. After a slow injection of a MB contrast via a tail vein catheter placed in breast cancer-bearing mice (N = 10), each tumor was US imaged for 10 min at baseline and again at 1 and 2 h after dosing with an antiangiogenic drug (bevacizumab, Genentech Inc) or sham control drug. After collecting a stack of US images, images corrupted by respiratory motion were removed using curve fit-based filtering. A singular value decomposition (SVD)-based spatiotemporal filter was then used to localize individual MBs. Subsequently, a SR-US image (i.e., MB density map) was generated by mapping the cumulative MB localizations. SR-US images were reviewed and longitudinal changes in the tumor microvascular network in response to treatment were evaluated. Overall, an acute microvascular response to bevacizumab was found within 2 h of drug dosing. This observation was consistent with immunohistologic findings and suggests that in vivo SR-US imaging has enormous potential in monitoring the early tumor response to drug treatment.

KW - Angiogenesis

KW - Bevacizumab

KW - Contrast Agents

KW - Microbubbles

KW - Microvascular Imaging

KW - Super-Resolution Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=85039452370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039452370&partnerID=8YFLogxK

U2 - 10.1109/ULTSYM.2017.8092944

DO - 10.1109/ULTSYM.2017.8092944

M3 - Conference contribution

AN - SCOPUS:85039452370

BT - 2017 IEEE International Ultrasonics Symposium, IUS 2017

PB - IEEE Computer Society

ER -